Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 364-369

  Lalezari, Jacob ^a   Sullivan, J Greg ^b   Varunok, Peter ^c   Galen, Edward ^d   Kowdley, Kris V ^e   Rustgi, Vinod ^f   Aguilar, Humberto ^g   Felizarta, Franco ^h   McGovern, Barbara ⁱ   King, Martin ⁱ   Polepally, Akshanth R ⁱ   Cohen, Daniel E ⁱ  

^a Quest Clinical Research   (United States)

^b Parkway Medical Center ^*  (United States)

^c Premier Medical Group of the Hudson Valley   (United States)

^d Northwest Gastroenterology Clinic   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g Louisiana Research Center   (United States)

^h Private Practice   (United States)

ⁱ ABBVIE INC   (United States)

Author keywords

Hepatitis C virus; Interferon free therapy; Opioid replacement therapy; People who inject drugs; Sustained virologic response

Indexed keywords

BILIRUBIN; BUPRENORPHINE PLUS NALOXONE; DASABUVIR; HEMOGLOBIN; METHADONE; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; BUPRENORPHINE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; NARCOTIC ANALGESIC AGENT; SULFONAMIDE; URACIL; VIRUS DNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HUMAN; INSOMNIA; IRRITABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; OPIATE SUBSTITUTION TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; SARCOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; OPIATE ADDICTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ANILIDES; ANTIVIRAL AGENTS; BUPRENORPHINE; CARBAMATES; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; RIBAVIRIN; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 84940905515     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.029     Document Type: Article

References (39)

1. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014;11:28-35.
2. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
3. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001;91:23-30.
4. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212-220.
5. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009;16:352-358.
6. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33:126-133.
7. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005;40:S304-S312.
8. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
9. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
10. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
11. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
12. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57:S80-S89.
13. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56:806-816.
14. Menon RM, Klein CE, Lawal AA, Chiu Y-L, Awni WM, Podsadecki TJ, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. HepDART. Kohala Coast, HI; 2009.
15. Lawitz E, Poordad F, DeJesus E, Kowdley K, Gaultier I, Cohen D, et al. 1187 ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012;56:S470.
16. Lawitz E, Marbury T, Campbell A, Dumas E, Kapoor M, Pilot-Matias T, et al. 1186 Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: First study in HCV genotype-1 (GT1)-infected treatment- naive subjects. J Hepatol 2012;56:S469-S470.
17. Poordad F, Lawitz E, DeJesus E, Kowdley KV, Gaultier I, Cohen DE, et al. 1206 ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3- day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012;56:S478.
18. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
19. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-232.
20. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
21. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012;19:829-835.
22. Treloar C, Rance J, Dore GJ, Grebely J. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. J Viral Hepat 2013;21:560-567.
23. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010;24:753-762.
24. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-288, 288, e281.
25. Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis 2013;57:1014-1020.
26. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54:1137-1144.
27. Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011;18:e104-e116.
28. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005;77:81-86.
29. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int 2013;33: 30-34.
30. Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-1122.
31. Menon RM, Badri P, Das U, Wang T, Polepally A, Khatri A, et al. Drug-Drug Interactions with Direct Acting Antiviral Combination Therapy of ABT-450/r, Ombitasvir and Dasabuvir. 54th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC); 2014 September 5-9, 2014; Washington D.C.; 2014. A-007.
32. Menon R, Badri P, Wang T, Polepally A, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol 2015;63:20-29.
33. COPEGUS (ribavirin) [package insert]. Genentech/Roche: South San Francisco, CA; 2013.
34. REBETOL (ribavirin) [package insert]. Merck & Co.: Whitehouse Station, NJ, USA; 2013.
35. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT- 450/r-Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
36. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-365.
37. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
38. Maieron A, Puoti M, Enejosa J, Andreone P, Ben Ari Z, Norkrans G, et al. SVR12 of 99% achieved with a ribavirin-free regimen of ABT-450/r/ ombitasvir and dasabuvir in HCV genotype 1b-infected patients. Vienna, Austria: United European Gastroenterology Week; 2014.
39. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013;57:S129-S137.